At-Home Lab Testing Market Report 2026

The at-home lab testing market size has grown strongly in recent years. It will grow from $11.14 billion in 2025 to $12.16 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to growing consumer preference for home-based healthcare, expansion of telehealth services, increasing awareness of preventive diagnostics, rising availability of mail-in testing kits, improvements in laboratory processing technologies.

The at-home lab testing market size is expected to see strong growth in the next few years. It will grow to $17.38 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for personalized health insights, rising adoption of genetic and hormone testing, expansion of digital diagnostics ecosystems, growing investments in home healthcare services, increasing focus on data-driven health management. Major trends in the forecast period include increasing adoption of self-collection diagnostic kits, rising demand for remote health monitoring solutions, growing integration of digital health platforms, expansion of direct-to-consumer testing services, enhanced focus on preventive healthcare.

The growth of personalized medicine is anticipated to drive the expansion of the at-home lab testing market in the future. Personalized medicine is a medical approach that customizes the prevention, diagnosis, and treatment of diseases according to an individual’s genetic, environmental, and lifestyle factors. The increase in personalized medicine is fueled by advancements in genomics, which allow the assessment of a person’s genetic profile to design medical treatments and interventions that are more precise, effective, and targeted. Personalized medicine enhances at-home lab testing by adapting diagnostic methods and recommendations to an individual’s genetic, lifestyle, and health characteristics, providing more accurate, actionable, and convenient healthcare insights. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, compared to six approvals in 2022. The 2023 approvals also included seven cancer drugs and three for other diseases and conditions. Consequently, the growth of personalized medicine is boosting the at-home lab testing market.

Key companies operating in the at-home lab testing market are focusing on developing innovative solutions, such as direct-to-consumer gut microbiome test kits, to provide personalized health insights without visiting clinics. A direct-to-consumer gut microbiome test kit is a product that allows individuals to collect a sample at home and receive analysis of their gut bacteria and personalized health insights without needing a doctor’s visit. For example, in January 2025, CJ Bioscience Inc., a South Korea-based biotech company, launched the gut microbiome testing service aimed at enabling personalized nutrition recommendations. The service, called SMILE GUT, allows users to collect a stool sample at home and receive a detailed analysis of their gut bacterial composition. Using AI and a database of over 140,000 profiles, the test generates a Gut Microbiome Index score and highlights areas for dietary or probiotic adjustments. The company also provides personalized food and supplement guidance, supporting overall gut health and paving the way for tailored functional food products.

In February 2025, Hims & Hers Health Inc., a US-based telehealth company, acquired Trybe Labs from Sigmund NJ LLC for an undisclosed amount. With this acquisition, Hims & Hers aimed to expand its offerings into at-home lab testing and blood draw capabilities to enhance its preventive care platform and provide deeper clinical insights directly to consumers. Sigmund NJ LLC is a US-based provider of at-home lab testing services, specializing in blood testing across a range of health markers for comprehensive wellness insights.

Major companies operating in the at-home lab testing market are Roche Diagnostics AG, Abbott Laboratories, Siemens Healthineers AG, Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, QuidelOrtho Corporation, OraSure Technologies Inc., 23andMe Holding Co., Everlywell Inc., Tiny Health Inc., Acon Laboratories Inc., Vault Health Inc., iHealth Labs Inc., Healthy.io Ltd., Getlabs Inc., Thriva Ltd., BioIQ Inc., myLAB Box LLC, Medichecks.com Ltd.

Tariffs are impacting the at-home lab testing market by increasing costs of imported diagnostic reagents, test kit components, medical-grade plastics, and laboratory equipment used in sample analysis and processing. North America and Europe are most affected due to reliance on imported consumables and testing devices, while Asia-Pacific faces cost pressures on export-oriented kit manufacturing. These tariffs are raising test kit prices and affecting affordability for consumers. However, they are also encouraging domestic production of diagnostic kits, regional laboratory expansion, and innovation in cost-efficient and scalable at-home testing solutions.

The at-home lab testing market research report is one of a series of new reports that provides at-home lab testing market statistics, including at-home lab testing industry global market size, regional shares, competitors with a at-home lab testing market share, detailed at-home lab testing market segments, market trends and opportunities, and any further data you may need to thrive in the at-home lab testing industry. This at-home lab testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

At-home lab testing refers to diagnostic services that enable individuals to collect biological samples, including blood, saliva, urine, or swabs, within their homes using self-sampling kits, which are then sent or digitally submitted to accredited laboratories for analysis and results delivery. These services enhance accessibility, convenience, and privacy while supporting early diagnosis, ongoing monitoring, and management of multiple health conditions without requiring in-person medical visits.

The primary types of at-home lab testing include glucose test kits, infectious disease test kits, pregnancy and fertility test kits, cholesterol and lipid test kits, genetic test kits, hormone test kits, allergy test kits, drug and alcohol test kits, coagulation and international normalized ratio (INR) test kits, and other test kits. Glucose test kits refer to kits designed for individuals to monitor blood glucose levels at home to manage or detect diabetes. These kits utilize sample types such as blood, saliva, urine, swab samples, and other sample types. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by end users including individuals, healthcare providers, employers and organizations, and other end users.

The at-home lab testing market includes revenues earned by entities by providing services such as blood testing services, genetic testing services, infectious disease testing services, hormone testing services, allergy testing services, and fertility testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.